Edwards Lifesciences Officer Executes Routine 10b5-1 Stock Option Exercise & Sale
Edwards Lifesciences Corp
Subscribe to track EW
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Insider Transaction Report | Edwards Lifesciences Corp ($EW)
Insider: Daniel J. Lippis (CVP, TAVR) Transaction Date: September 11, 2026 Filing Date: September 11, 2026
Transaction Overview: ā¢ Action: Option Exercise & Sale (Rule 10b5-1 Plan) ā¢ Shares Sold: 619 shares @ $87.51 ($54,168.69 total value) ā¢ Shares Acquired: 619 shares via option exercise @ $72.68 ā¢ Direct Ownership After: 40,033.91 shares
Significance: Low ā Routine pre-scheduled 10b5-1 transaction representing a minor portion of total holdings.
Comprehensive Analysis
Executive Summary
On September 11, 2026, Daniel J. Lippis, Corporate Vice President of TAVR at Edwards Lifesciences Corp ($EW), completed a standard stock option exercise and subsequent sale of 619 shares of common stock under a pre-established Rule 10b5-1 trading plan.
Transaction Details
- Option Exercise: 619 options exercised at an exercise price of $72.68 per share.
- Sale: 619 shares sold at an average price of $87.51 per share, generating total gross proceeds of approximately $54,168.69.
- Post-Transaction Holdings: Direct beneficial ownership stands at 40,033.9103 shares of common stock, alongside 3,714 remaining exercisable derivative stock options.
Strategic & Market Implications
- Trading Plan Execution: The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026, removing discretionary timing from the sale.
- Significance Level: Low. The trade represents a routine exercise-and-sell pattern involving a nominal dollar volume relative to the insider's total equity position.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.